ClinVar Miner

Submissions for variant NM_033028.5(BBS4):c.572A>G (p.Tyr191Cys)

dbSNP: rs756915341
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001210878 SCV001382387 uncertain significance Bardet-Biedl syndrome 2021-09-02 criteria provided, single submitter clinical testing This sequence change replaces tyrosine with cysteine at codon 191 of the BBS4 protein (p.Tyr191Cys). The tyrosine residue is moderately conserved and there is a large physicochemical difference between tyrosine and cysteine. This variant is present in population databases (rs756915341, ExAC 0.009%). This variant has not been reported in the literature in individuals affected with BBS4-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002484146 SCV002775389 uncertain significance Bardet-Biedl syndrome 4 2021-07-28 criteria provided, single submitter clinical testing
Ambry Genetics RCV002561745 SCV003555654 uncertain significance Inborn genetic diseases 2021-01-08 criteria provided, single submitter clinical testing The c.572A>G (p.Y191C) alteration is located in exon 8 (coding exon 8) of the BBS4 gene. This alteration results from a A to G substitution at nucleotide position 572, causing the tyrosine (Y) at amino acid position 191 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003414003 SCV004107906 uncertain significance BBS4-related condition 2023-01-31 criteria provided, single submitter clinical testing The BBS4 c.572A>G variant is predicted to result in the amino acid substitution p.Tyr191Cys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-73016981-A-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.